{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T19:29:36Z","timestamp":1783711776939,"version":"3.55.0"},"reference-count":37,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2004,10,15]],"date-time":"2004-10-15T00:00:00Z","timestamp":1097798400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis AG","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Bendheim Parkinson Disease Centre"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Movement Disorders"],"published-print":{"date-parts":[[2005,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Long\u2010acting dopamine agonist drugs induce a lower incidence of dyskinesia in MPTP\u2010treated primates and patients with Parkinson's disease compared to pulsatile treatment with levodopa, supporting the concept of continuous dopaminergic stimulation as a means of dyskinesia avoidance. We examined the effects of <jats:sc>L<\/jats:sc>\u2010dopa administered with or without the COMT inhibitor entacapone on dyskinesia induction in previously untreated MPTP\u2010treated common marmosets. Administration of <jats:sc>L<\/jats:sc>\u2010dopa (12.5 mg\/kg p.o.) plus carbidopa twice daily produced fluctuating improvement in motor behavior coupled with dyskinesia. Coadministration with entacapone produced similar patterns of motor improvement and dyskinesia that were not different from that produced by <jats:sc>L<\/jats:sc>\u2010dopa alone. Treatment with <jats:sc>L<\/jats:sc>\u2010dopa (6.25 mg\/kg p.o.) plus carbidopa four times daily reversed motor disability and induced dyskinesia in a manner that was not different from the twice\u2010daily treatment regimens. However, coadministration with entacapone produced more continuous improvement in locomotor activity with less dyskinesia than animals treated with <jats:sc>L<\/jats:sc>\u2010dopa four times daily alone. These data support the notion that pulsatile stimulation contributes to the development of dyskinesia and suggests that more frequent dosing of <jats:sc>L<\/jats:sc>\u2010dopa plus entacapone may be a useful treatment strategy for patients in the early stages of Parkinson's disease. \u00a9 2004 Movement Disorder Society<\/jats:p>","DOI":"10.1002\/mds.20317","type":"journal-article","created":{"date-parts":[[2004,10,15]],"date-time":"2004-10-15T19:00:34Z","timestamp":1097866834000},"page":"306-314","source":"Crossref","is-referenced-by-count":98,"title":["Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP\u2010treated drug\u2010na\u00efve primates"],"prefix":"10.1002","volume":"20","author":[{"given":"Lance A.","family":"Smith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghassan","family":"Al\u2010Barghouthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Rose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikko","family":"Kuoppamaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warren","family":"Olanow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Jenner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2005,3,9]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(76)91416-1"},{"key":"e_1_2_6_3_2","first-page":"89","volume-title":"The scientific basis for the treatment of Parkinson's disease","author":"Fahn S","year":"1992"},{"key":"e_1_2_6_4_2","first-page":"11","volume-title":"Beyond the decade of the brain","author":"Obeso J","year":"1997"},{"issue":"1","key":"e_1_2_6_5_2","first-page":"S167","article-title":"Preventing levodopa\u2010induced dyskinesias","volume":"47","author":"Olanow CW","year":"2000","journal-title":"Ann Neurol"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1360-0443.95.8s2.1.x"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/nn1103"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1471-1931(00)00030-6"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(86)90783-3"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870130207"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.284.15.1931"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200005183422004"},{"key":"e_1_2_6_13_2","first-page":"37","volume-title":"Dopamine agonists in early Parkinson's disease","author":"Olanow CW","year":"1997"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.56.suppl_5.S1"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)09733-7"},{"issue":"1","key":"e_1_2_6_16_2","first-page":"S90","article-title":"Factors influencing the onset and persistence of dyskinesia in MPTP\u2010treated primates","volume":"47","author":"Jenner P","year":"2000","journal-title":"Ann Neurol"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.1149"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-199304000-00007"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-199619040-00001"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200059060-00004"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/s702-002-8237-z"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.10394"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410270105"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.43.8.1545"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870130222"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02245479"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870100606"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.102.039743"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870120616"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-200005000-00002"},{"key":"e_1_2_6_31_2","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0022-3565(25)24503-7","article-title":"Continuous administration decreases and pulsatile administration increases behavioral sensitivity to a novel dopamine D2 agonist (U\u201091356A) in MPTP\u2010exposed monkeys","volume":"272","author":"Blanchet PJ","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(96)00157-6"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199855001-00004"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.53.3.573"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awf214"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.1996.tb00163.x"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1159\/000117399"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.53.5.1012"}],"container-title":["Movement Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.20317","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.20317","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T13:34:13Z","timestamp":1760967253000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mds.20317"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,3]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,3]]}},"alternative-id":["10.1002\/mds.20317"],"URL":"https:\/\/doi.org\/10.1002\/mds.20317","archive":["Portico"],"relation":{},"ISSN":["0885-3185","1531-8257"],"issn-type":[{"value":"0885-3185","type":"print"},{"value":"1531-8257","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,3]]}}}